Mayne Pharma Group Ltd
ASX:MYX
Mayne Pharma Group Ltd
Net Income (Common)
Mayne Pharma Group Ltd
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Mayne Pharma Group Ltd
ASX:MYX
|
Net Income (Common)
AU$117.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Net Income (Common)
-AU$11.3m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Net Income (Common)
AU$157.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
120%
|
CAGR 10-Years
N/A
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Net Income (Common)
-AU$14.6m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-24%
|
|
Probiotec Ltd
ASX:PBP
|
Net Income (Common)
AU$8.7m
|
CAGR 3-Years
29%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
21%
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Net Income (Common)
-AU$24.6m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Mayne Pharma Group Ltd's Net Income (Common)?
Net Income (Common)
117.2m
AUD
Based on the financial report for Jun 30, 2023, Mayne Pharma Group Ltd's Net Income (Common) amounts to 117.2m AUD.